Management of malignant pleural mesothelioma: a critical review.
Malignant mesothelioma remains a uniformly fatal disease and best supportive care continues to be the standard treatment. Neither chemotherapy nor surgery has been shown to prolong survival. Radiotherapy is not curative but is useful for prophylaxis against needle-track metastases and for symptom palliation. Combinations of therapies have been tried but most studies were uncontrolled and selection bias makes the results impossible to interpret. The combination of extrapleural pneumonectomy, chemotherapy, and radiotherapy attracted much interest, but the subsequent results were disappointing in a highly selected group of patients. Randomized controlled trials are desperately needed to provide definitive information on experimental treatments. It is also important to develop better measures of disease response and to assess quality of life issues in clinical trials. If patients are to receive therapies other than palliation, they should only do so in the setting of randomized controlled trials under approved protocols.
Lee
Y C
YC
St Thomas Hospital/Vanderbilt University, Nashville, Tennessee 37202, USA. ycgarylee@hotmail.com
Light
R W
RW
Musk
A W
AW
D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D010166:Palliative Care; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic